AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28875250 — intervention group
Group type: COMPARATOR
Intervention: Non-iris registration FEMTOLASIK
Number of subjects: 59
Study 26689403 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn screening (NBS)
Number of subjects: 567
Study 26689403 — intervention group
Group type: COMPARATOR
Intervention: Late onset (LO) patients
Number of subjects: 567
Study 26689403 — intervention group
Group type: COMPARATOR
Intervention: Various metabolic treatment strategies
Number of subjects: 567
Study 22716232 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-legged heel-rise test
Number of subjects: 81
Study 22716232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to perform a heel-rise
Number of subjects: 81
Study 22716232 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 81
Study 22356470 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA 500U
Number of subjects: 252
Study 22356470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 19742382 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group (participants chose their preferred treatment)
Number of subjects: 73
Study 19742382 — intervention group
Group type: EXPERIMENTAL
Intervention: No choice group (participants were assigned to their preferred treatment but believed they couldn't choose)
Number of subjects: 73
Study 19742382 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (participants received no treatment until the end of the study)
Number of subjects: 73
Study 18533842 — intervention group
Group type: EXPERIMENTAL
Intervention: Children (<10 years)
Number of subjects: 1050
Study 18533842 — intervention group
Group type: COMPARATOR
Intervention: Adults (21-50 years)
Number of subjects: 1050
Study 18533842 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (>50 years)
Number of subjects: 1050
Study 18533842 — intervention group
Group type: EXPERIMENTAL
Intervention: All ages
Number of subjects: 1050
Study 15321434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.15 mg
Number of subjects: 80
Study 15321434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 80
Study 15321434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg
Number of subjects: 80
Study 15321434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12904147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant treatment
Number of subjects: 0
Study 12904147 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for anticoagulant-related bleeding
Number of subjects: 0
Study 9822268 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 24
Study 7916025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% metipranolol HCl + 2% pilocarpine HCl
Number of subjects: 19
Study 7916025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% metipranolol HCl + 4% pilocarpine HCl
Number of subjects: 19
Study 7916025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% metipranolol HCl + 2% pilocarpine HCl
Number of subjects: 19
Study 7916025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% metipranolol HCl + 4% pilocarpine HCl
Number of subjects: 19
Study 7916025 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 19
Study 7916025 — intervention group
Group type: COMPARATOR
Intervention: 0.1% metipranolol HCl
Number of subjects: 19
Study 7916025 — intervention group
Group type: COMPARATOR
Intervention: 0.3% metipranolol HCl
Number of subjects: 19
Study 7916025 — intervention group
Group type: COMPARATOR
Intervention: 2% pilocarpine HCl
Number of subjects: 19
Study 7916025 — intervention group
Group type: COMPARATOR
Intervention: 4% pilocarpine HCl
Number of subjects: 19
Study 2473952 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 31
Study 2473952 — intervention group
Group type: COMPARATOR
Intervention: Inosine pranobex
Number of subjects: 31
Study 702219 — intervention group
Group type: EXPERIMENTAL
Intervention: HDFP treatment (step-wise pharmacologic regimen)
Number of subjects: 513
Study 702219 — intervention group
Group type: COMPARATOR
Intervention: Control group (referred to their physicians for treatment)
Number of subjects: 513
Study 31645614 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted gene co-expression network analysis (WGCNA)
Number of subjects: 0
Study 31645614 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounds affecting anti-inflammatory pathways and drugs targeting coagulation pathways
Number of subjects: 0
Study 27251666 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal blood transfusion strategy (Hb levels ≥11.3 g/dL)
Number of subjects: 179
Study 27251666 — intervention group
Group type: COMPARATOR
Intervention: Restrictive blood transfusion strategy (Hb levels ≥9.7 g/dL)
Number of subjects: 179
Study 27251666 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal blood transfusion strategy (LB)
Number of subjects: 179
Study 27251666 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of postoperative delirium (POD)
Number of subjects: 179
Study 25869371 — intervention group
Group type: EXPERIMENTAL
Intervention: Support‐Transform‐Achieve‐Results Intervention
Number of subjects: 93
Study 25869371 — intervention group
Group type: COMPARATOR
Intervention: Usual Practice group
Number of subjects: 93
Study 22628369 — intervention group
Group type: EXPERIMENTAL
Intervention: Group condition (immediate intervention)
Number of subjects: 80
Study 22628369 — intervention group
Group type: COMPARATOR
Intervention: Individual condition (delayed intervention)
Number of subjects: 80
Study 21654270 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d febuxostat
Number of subjects: 0
Study 21654270 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/d febuxostat
Number of subjects: 0
Study 19344008 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Clinical Decision Support System (CDSS) intervention with reminders every 4 months
Number of subjects: 56
Study 19344008 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 56
Study 19344008 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequately treated with lipid-lowering drugs
Number of subjects: 56
Study 16885248 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations involving product requests
Number of subjects: 364
Study 16885248 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus group assessment (stage 1)
Number of subjects: 364
Study 16885248 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert group assessment (stage 2)
Number of subjects: 364
Study 15492650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 8 mm Hg
Number of subjects: 100
Study 15492650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 10 mm Hg
Number of subjects: 100
Study 15492650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 12 mm Hg
Number of subjects: 100
Study 15492650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 14 mm Hg
Number of subjects: 100
Study 15492650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure level of 16 mm Hg
Number of subjects: 100
Study 11280362 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tapping implants
Number of subjects: 189
Study 11280362 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE implants
Number of subjects: 189
Study 11280362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both self-tapping and ICE implants
Number of subjects: 189
Study 9174453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless knee prostheses (3 designs)
Number of subjects: 42
Study 2948526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (400 micrograms)
Number of subjects: 14
Study 29663011 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet+extra‐virgin olive oil
Number of subjects: 945
Study 29663011 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 945
Study 29663011 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet+nuts
Number of subjects: 945
Study 29663011 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of phenylalanine
Number of subjects: 945
Study 29663011 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of leucine
Number of subjects: 945
Study 27217043 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 189
Study 24382690 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimize group (telbivudine for 24 weeks, then telbivudine plus adefovir until week 104 for suboptimal responders)
Number of subjects: 606
Study 24382690 — intervention group
Group type: COMPARATOR
Intervention: Mono group (telbivudine monotherapy)
Number of subjects: 606
Study 24382690 — intervention group
Group type: EXPERIMENTAL
Intervention: telbivudine plus adefovir (for week 24 suboptimal responders)
Number of subjects: 606
Study 24382690 — intervention group
Group type: COMPARATOR
Intervention: telbivudine monotherapy
Number of subjects: 606
Study 23208461 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/HMG/GnRHant group (n=40)
Number of subjects: 82
Study 23208461 — intervention group
Group type: COMPARATOR
Intervention: HMG/GnRHant group (n=42)
Number of subjects: 82
Study 20385680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 524
Study 20385680 — intervention group
Group type: EXPERIMENTAL
Intervention: Local guidelines recommending routine use of oxygen
Number of subjects: 524
Study 20385680 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in oxygen's effectiveness
Number of subjects: 524
Study 20385680 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about oxygen therapy
Number of subjects: 524
Study 18222241 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde hot-shot cardioplegia
Number of subjects: 36
Study 18222241 — intervention group
Group type: COMPARATOR
Intervention: Cold-blood cardioplegia
Number of subjects: 36
Study 18222241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 16754218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo-preparation (local ice application before injection)
Number of subjects: 39
Study 16754218 — intervention group
Group type: COMPARATOR
Intervention: No cryo-preparation (standard local anaesthetic injection)
Number of subjects: 39
Study 12663710 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+TAB
Number of subjects: 149
Study 12663710 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 149
Study 10837839 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Diet Coke (76 mg caffeine)
Number of subjects: 11
Study 10837839 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free Diet Coke (10 mg caffeine)
Number of subjects: 11
Study 10837839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both beverages (Regular and Caffeine-free Diet Coke)
Number of subjects: 11
Study 8644660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 356
Study 8644660 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 356
Study 1632305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprostene
Number of subjects: 32
Study 1632305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3777568 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 20
Study 3777568 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study 31494254 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Vivomixx® (2 sachets twice daily for 2 months)
Number of subjects: 80
Study 31494254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29351383 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-joint exercises (MJ)
Number of subjects: 30
Study 29351383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multi- and single-joint exercises (MJ+SJ)
Number of subjects: 30
Study 29351383 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 27597270 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 400
Study 27597270 — intervention group
Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 400
Study 25415784 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections
Number of subjects: 220
Study 25415784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections with local anesthetic only
Number of subjects: 220
Study 25415784 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic and steroid
Number of subjects: 220
Study 25415784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections with local anesthetic and steroid
Number of subjects: 220
Study 25415784 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic only
Number of subjects: 220
Study 22721899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide (ViCPS) vaccine
Number of subjects: 27231
Study 22721899 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 27231
Study 20178577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch conditions in an auditory identification task
Number of subjects: 14
Study 18628532 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk pregnancy screening
Number of subjects: 299
Study 18628532 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age and parity
Number of subjects: 299
Study 18628532 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal educational attainment
Number of subjects: 299
Study 18628532 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors
Number of subjects: 299
Study 18325758 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch 30 cm2 (0.5mg/cm2)
Number of subjects: 24
Study 18325758 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch 45 cm2 (0.5mg/cm2)
Number of subjects: 24
Study 18325758 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch 60 cm2 (0.5mg/cm2)
Number of subjects: 24
Study 15073677 — intervention group
Group type: EXPERIMENTAL
Intervention: Smallpox immunization with vaccinia virus (VV)
Number of subjects: 0
Study 11739447 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8, 1 ng/kg per min
Number of subjects: 24
Study 11739447 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8, 3 ng/kg per min
Number of subjects: 24
Study 11739447 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 11739447 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 infusion
Number of subjects: 24
Study 9422926 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam radiotherapy
Number of subjects: 127
Study 7684118 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine (3 g/day)
Number of subjects: 32
Study 7684118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3320786 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 13
Study 3320786 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13
Study 3320786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Verapamil and Propranolol
Number of subjects: 13
Study 31084359 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusive chaos method
Number of subjects: 135
Study 28566070 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement initiative comprising point‐of‐care electronic decision support with audit and feedback tools
Number of subjects: 53164
Study 25612299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 2.5 mg b.i.d.
Number of subjects: 0
Study 25612299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 5 mg b.i.d.
Number of subjects: 0
Study 25612299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 10 mg q.d.
Number of subjects: 0
Study 25612299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 20 mg q.d.
Number of subjects: 0
Study 25612299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 20 mg single dose after washout period
Number of subjects: 0
Study 25612299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 2.5 mg b.i.d. and 5 mg b.i.d. morning doses
Number of subjects: 0
Study 23930631 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 percent sodium hypochlorite (NaOCl)
Number of subjects: 100
Study 23930631 — intervention group
Group type: COMPARATOR
Intervention: formocresol (FC)
Number of subjects: 100
Study 21114477 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer containing formaldehyde (2000 p.p.m.)
Number of subjects: 37
Study 21114477 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer without formaldehyde
Number of subjects: 37
Study 19858753 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine + D-pinitol (CRP)
Number of subjects: 24
Study 19858753 — intervention group
Group type: COMPARATOR
Intervention: Creatine monohydrate (CR)
Number of subjects: 24
Study 16768642 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 18-72 mg/day
Number of subjects: 171
Study 15315724 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser
Number of subjects: 40
Study 15315724 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 40
Study 11167103 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 48
Study 11167103 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF)
Number of subjects: 48
Study 11167103 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 9266276 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-299 0.8 mg
Number of subjects: 37
Study 9266276 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-299 2 mg
Number of subjects: 37
Study 9266276 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-299 70 mg
Number of subjects: 37
Study 9266276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8281717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow fiber dialyzer GF 120M
Number of subjects: 14
Study 8281717 — intervention group
Group type: COMPARATOR
Intervention: Plate dialyzer Lundia IC5N
Number of subjects: 14
Study 3822616 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole (5 mg/kg/day)
Number of subjects: 80
Study 3822616 — intervention group
Group type: COMPARATOR
Intervention: griseofulvin (15 mg/kg/day)
Number of subjects: 80
Study 29803589 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 80
Study 29803589 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 80
Study 27491620 — intervention group
Group type: EXPERIMENTAL
Intervention: SL group (lowered glycogen availability)
Number of subjects: 21
Study 27491620 — intervention group
Group type: COMPARATOR
Intervention: CON group (maintained glycogen availability)
Number of subjects: 21
Study 27491620 — intervention group
Group type: EXPERIMENTAL
Intervention: SL group
Number of subjects: 21
Study 27491620 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 21
Study 24297666 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on knowledge
Number of subjects: 446
Study 24297666 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on quality of care
Number of subjects: 446
Study 24297666 — intervention group
Group type: EXPERIMENTAL
Intervention: Useful feedback on knowledge
Number of subjects: 446
Study 24297666 — intervention group
Group type: EXPERIMENTAL
Intervention: Useful feedback on clinical care
Number of subjects: 446
Study 24297666 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in knowledge assessment programs
Number of subjects: 446
Study 24297666 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstrating knowledge via examination
Number of subjects: 446
Study 24297666 — intervention group
Group type: EXPERIMENTAL
Intervention: Public availability of competence information
Number of subjects: 446
Study 22503494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1000 mg of paracetamol
Number of subjects: 102
Study 22503494 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of 50 mg of pethidine hydrochloride
Number of subjects: 102
Study 20455609 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruptive confederate child
Number of subjects: 90
Study 20455609 — intervention group
Group type: COMPARATOR
Intervention: Typical confederate child
Number of subjects: 90
Study 18833865 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Xtra Boost (38% HP)
Number of subjects: 36
Study 18833865 — intervention group
Group type: EXPERIMENTAL
Intervention: Easywhite Ready (30% HP) with plasma unit
Number of subjects: 36
Study 18833865 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoom2 system (25% HP with the Zoom2 unit)
Number of subjects: 36
Study 18833865 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 36
Study 16094267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute betadine solution irrigation (3.5% betadine) before wound closure
Number of subjects: 414
Study 16094267 — intervention group
Group type: COMPARATOR
Intervention: No betadine irrigation (control group)
Number of subjects: 414
Study 12577416 — intervention group
Group type: EXPERIMENTAL
Intervention: Langchuangding (LCD) plus glucocorticoid (GCC)
Number of subjects: 45
Study 12577416 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid (GCC) alone
Number of subjects: 45
Study 9647028 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (13-15 mg/kg/day)
Number of subjects: 180
Study 7518815 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined external irradiation and chemotherapy (bleomycin or peplomycin)
Number of subjects: 162
Study 2923425 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulated group (n = 41) received hourly aliquots of oral fluid as determined by twice daily ward rounds.
Number of subjects: 90
Study 2923425 — intervention group
Group type: COMPARATOR
Intervention: Unregulated group (n = 49) were given a jug of water and instructed to drink as desired.
Number of subjects: 90